Premium
Factors Associated with Increased HPV Vaccine Use in Rural‐Frontier U.S. States
Author(s) -
Lai Djin,
Ding Qian,
Bodson Julia,
Warner Echo L.,
Kepka Deanna
Publication year - 2015
Publication title -
public health nursing
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.471
H-Index - 55
eISSN - 1525-1446
pISSN - 0737-1209
DOI - 10.1111/phn.12223
Subject(s) - medicine , confidence interval , demography , vaccination , poisson regression , multivariate analysis , pediatrics , population , immunology , environmental health , sociology
Objective This study sought to examine sociodemographic factors surrounding human papillomavirus ( HPV ) vaccine initiation and three‐dose completion rates in the Intermountain West ( IW ). Design and Sample Analysis of the Centers for Disease Control and Prevention's 2012 National Immunization Survey‐Teen dataset was conducted with a survey‐weighted Pearson chi‐square test and multivariable Poisson regression to produce bivariate and multivariate analyses. Participants with daughters aged 13–17 with provider‐verified immunization records were included. Dual‐frame adjusted prevalence ratios ( PR ) and 95% confidence intervals ( CI ) were produced with provider‐phase sampling weights. Measures Factors included parents' and adolescents' sociodemographic and healthcare usage variables. Outcome measures included adolescents' receipt and completion of the HPV vaccine. Results Older parental ages (45 years and above) showed lower prevalence of adolescent HPV vaccine initiation ( PR = 0.73, 95% CI = 0.59–0.87, p = .003) and completion ( PR = 0.65, 95% CI = 0.44–0.96, p = .031) compared with parents younger than 35. Seventeen‐year‐old adolescents demonstrated highest prevalence of initiating ( PR = 1.88, 95% CI = 1.47–2.39, p < .001) and completing ( PR = 2.92, 95% CI = 1.97–4.33, p < .001) the vaccination series compared to 13‐year olds. Those who had received meningitis vaccinations had high prevalence of initiating ( PR = 1.93, 95% CI = 1.50–2.48, p < .001) and completing the HPV vaccine ( PR = 2.52, 95% CI = 1.64–3.86, p < .001). Conclusion This study highlights parental, adolescent, and health care characteristics related to use of the HPV vaccine. Future research to investigate specific barriers and strategies for addressing HPV vaccination use in the IW is recommended.